Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Biomarker-agnostic detection

Electronic nose uses AI to “smell” ovarian cancer

Using machine learning, researchers have trained an electronic nose to detect early signs of ovarian cancer in the blood. The method could eventually be used to find many different cancers.

News • Advance in embryo selection

"Invisible" culture dishes improve the odds for IVF

Selecting the healthiest embryo is one of the most important steps in in‑vitro fertilization, yet it remains one of the most uncertain. A new type of hydrogel offers hope for more successful IVF.

News • Liquid handling

New solution for low-volume dispensing presented at SLAS 2026

Analytik Jena will be presenting new automation solutions for laboratory workflows at the SLAS 2026 International Conference & Exhibition (February 7–11). A particular highlight is the launch…

Related articles